OM
RNAC icon

Opaleye Management’s Cartesian Therapeutics RNAC Stock Holding History

Opaleye Management’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-3,533
Closed -$441K – 45
2021
Q3 		$441K Buy
+3,533
New +$427K 0.08% 46
2020
Q2 		– Sell
-13,000
Closed -$940K – 52
2020
Q1 		$940K Buy
+13,000
New +$1.26M 0.25% 40
2017
Q4 		– Sell
-3,167
Closed -$1.73M – 39
2017
Q3 		$1.73M Buy
+3,167
New +$1.68M 0.61% 29

Other funds holding RNAC

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
N
NanoDimension Woodside, California $24.7M AUM 74.01% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Opaleye Management's RNAC Position: Q4 2021 in Review

Opaleye Management sold out of Cartesian Therapeutics (RNAC) in Q4 2021, closing a stake of 3,533 shares — an estimated $441K sold.

Opaleye Management first reported a position in RNAC in Q3 2017 and held it in 3 quarters. The position peaked at $1.73M in Q3 2017. 106 funds tracked by Wall St. Rank hold RNAC as of Q4 2021.

  • Opaleye Management reported no remaining Cartesian Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Opaleye Management sold 3,533 Cartesian Therapeutics shares in Q4 2021, an estimated $441K.
  • Opaleye Management first reported a position in Cartesian Therapeutics in Q3 2017 and held it in 3 quarters.
  • Opaleye Management's Cartesian Therapeutics position peaked at $1.73M in Q3 2017.
  • 106 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q4 2021.

Based on Opaleye Management's 13F filing for Q4 2021, filed 14 Feb 2022.